Amryt to expand rare disease portfolio with $311m Aegerion mergerRare disease specialist Amryt Pharma plans to expand its rare disease portfolio with the acquisition of troubled Aegerion Share XAmryt to expand rare disease portfolio with $311m Aegerion mergerhttps://pharmaphorum.com/news/amryt-to-expand-rare-disease-portfolio-with-311m-aegerion-merger/
Amryt looking to expand rare disease franchiseAmryt looking to expand rare disease franchise Share XAmryt looking to expand rare disease franchisehttps://pharmaphorum.com/news/amryt-looking-expand-rare-disease-franchise/